Funding Opportunity RFA-HL-17-023 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active R43/R44 Small Business Innovation Research Grants (SBIR) awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.

Notice NOT-HL-17-510 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-011 from the NIH Guide for Grants and Contracts

Notice NOT-RM-17-024 from the NIH Guide for Grants and Contracts

Notice NOT-LM-17-005 from the NIH Guide for Grants and Contracts

Notice NOT-NS-17-027 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-062 from the NIH Guide for Grants and Contracts

Notice NOT-HS-17-015 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-17-508 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator (PD/PI) of the current Data Coordinating Center (DCC) for The Environmental Determinants of Diabetes in the Young (TEDDY) study, an ongoing epidemiological study. This DCC has been involved in study design and data and biosample acquisition and management since the inception of the TEDDY Consortium. This FOA provides support for the TEDDY DCC to continue to follow TEDDY children, allowing collaborators to conduct further studies in the measurement and analysis of immune markers using samples from TEDDY subjects.

Notice NOT-OD-17-059 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-004 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-003 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-006 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-005 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-008 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-007 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-010 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-009 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-18-006 from the NIH Guide for Grants and Contracts. The purpose of this Small Business Technology Transfer (STTR) RFA is to develop a nasal delivery formulation that reliably delivers of a therapeutic (e.g., peptides, antibodies, RNAi, or pharmacotherapeutics), at a physiologically relevant concentration, into the central nervous system (CNS).

Funding Opportunity RFA-DA-18-007 from the NIH Guide for Grants and Contracts. The purpose of this Small Business Technology Transfer (STTR) RFA is to develop a nasal delivery formulation that reliably delivers of a therapeutic (e.g., peptides, antibodies, RNAi, or pharmacotherapeutics), at a physiologically relevant concentration, into the central nervous system (CNS).